The bill removes the requirement for provisional consent to be granted on a restricted basis for the treatment of a limited number of patients. In doing so, it should be clear that this provision, perhaps referencing concerns about orphan drugs, did not protect safety. That was always achieved through the risk assessment prescribed in section 22(1).